Danimer Scientific Key Executives
This section highlights Danimer Scientific's key executives, including their titles and compensation details.
Find Contacts at Danimer Scientific
(Showing 0 of )
Danimer Scientific Earnings
This section highlights Danimer Scientific's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2024 | 2024-11-19 | $-0.20 | $-0.24 |
| Read Transcript | Q1 | 2024 | 2024-05-07 | $-12.00 | $-10.40 |
| Read Transcript | Q4 | 2023 | 2024-03-28 | $-15.60 | $-15.60 |
| Read Transcript | Q3 | 2023 | 2023-11-14 | $-13.60 | $-15.60 |
| Read Transcript | Q2 | 2023 | 2023-08-08 | $-14.40 | $-15.20 |
| Read Transcript | Q1 | 2023 | 2023-05-10 | $-14.00 | $-14.40 |
Financial Statements
Access annual & quarterly financial statements for Danimer Scientific, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $46.68M | $53.22M | $58.75M | $47.33M | $32.34M |
| Cost of Revenue | $73.64M | $63.63M | $57.87M | $35.88M | $21.24M |
| Gross Profit | $-26.96M | $-10.41M | $884.00K | $11.46M | $11.11M |
| Gross Profit Ratio | -57.75% | -19.57% | 1.50% | 24.21% | 34.34% |
| Research and Development Expenses | $29.24M | $31.94M | $20.27M | $7.85M | $5.48M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $68.98M | $81.59M | $80.00M | $19.34M | $16.03M |
| Other Expenses | $434.00K | $723.00K | $-44.00K | $-31.00K | $277.00K |
| Operating Expenses | $98.66M | $113.53M | $100.27M | $27.19M | $21.51M |
| Cost and Expenses | $172.30M | $177.16M | $158.14M | $63.07M | $42.75M |
| Interest Income | $- | $1.72M | $763.00K | $347.00K | $340.00K |
| Interest Expense | $- | $112.25M | $763.00K | $2.43M | $3.48M |
| Depreciation and Amortization | $29.06M | $20.09M | $11.67M | $4.61M | $3.51M |
| EBITDA | $-96.13M | $-103.49M | $-87.72M | $-10.30M | $-6.89M |
| EBITDA Ratio | -205.91% | -194.46% | -149.31% | -21.76% | -21.32% |
| Operating Income | $-125.62M | $-187.43M | $-99.39M | $-15.74M | $-10.40M |
| Operating Income Ratio | -269.08% | -352.20% | -169.18% | -33.25% | -32.16% |
| Total Other Income Expenses Net | $-29.54M | $6.87M | $26.13M | $6.88M | $-5.03M |
| Income Before Tax | $-155.15M | $-180.57M | $-73.34M | $-12.57M | $-15.43M |
| Income Before Tax Ratio | -332.35% | -339.30% | -124.84% | -26.56% | -47.70% |
| Income Tax Expense | $319.00K | $-810.00K | $-13.23M | $2.40M | $4.08M |
| Net Income | $-155.47M | $-179.76M | $-60.11M | $-14.97M | $-19.51M |
| Net Income Ratio | -333.03% | -337.78% | -102.31% | -31.62% | -60.33% |
| EPS | $-1.52 | $-1.78 | $-0.65 | $-0.18 | $-0.77 |
| EPS Diluted | $-1.52 | $-1.78 | $-0.65 | $-0.18 | $-0.77 |
| Weighted Average Shares Outstanding | 102.00M | 101.10M | 93.08M | 84.54M | 25.37M |
| Weighted Average Shares Outstanding Diluted | 102.00M | 101.10M | 93.08M | 84.54M | 25.37M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.63M | $7.63M | $10.22M | $10.95M | $10.95M | $12.87M | $11.93M | $15.32M | $10.45M | $12.70M | $14.74M | $17.73M | $13.37M | $14.47M | $13.18M | $12.03M | $12.84M | $11.87M | $10.60M | $8.73M |
| Cost of Revenue | $15.95M | $14.53M | $18.92M | $19.54M | $18.68M | $19.43M | $18.21M | $18.03M | $14.50M | $14.93M | $16.07M | $20.08M | $13.60M | $12.46M | $11.72M | $10.82M | $9.19M | $8.44M | $7.43M | $5.71M |
| Gross Profit | $-7.32M | $-6.90M | $-8.70M | $-8.59M | $-7.74M | $-6.57M | $-6.28M | $-2.70M | $-4.05M | $-2.23M | $-1.32M | $-2.35M | $-232.00K | $2.01M | $1.46M | $1.21M | $3.65M | $3.43M | $3.17M | $3.02M |
| Gross Profit Ratio | -84.76% | -90.50% | -85.04% | -78.50% | -70.67% | -51.05% | -52.68% | -17.63% | -38.81% | -17.56% | -8.97% | -13.27% | -1.74% | 13.90% | 11.05% | 10.05% | 28.41% | 28.91% | 29.90% | 34.59% |
| Research and Development Expenses | $4.58M | $5.11M | $3.31M | $5.68M | $6.88M | $7.71M | $7.08M | $7.47M | $7.95M | $8.91M | $7.13M | $8.67M | $5.01M | $3.98M | $2.62M | $2.29M | $2.19M | $2.13M | $1.25M | $1.97M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $197.70K | $112.33K | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.17M | $2.72M | $- | $- |
| Selling General and Administrative Expenses | $6.86M | $6.75M | $6.52M | $16.56M | $16.55M | $16.84M | $18.70M | $19.55M | $19.41M | $20.98M | $22.24M | $24.21M | $26.59M | $19.08M | $10.12M | $10.16M | $3.37M | $2.83M | $2.98M | $4.42M |
| Other Expenses | $65.00K | $565.00K | $- | $200.00K | $64.00K | $- | $170.00K | $399.00K | $240.00K | $75.00K | $9.00K | $-62.00K | $90.00K | $30.00K | $50.00K | $-66.00K | $108.00K | $99.00K | $90.00K | $- |
| Operating Expenses | $11.51M | $12.43M | $9.83M | $22.24M | $23.50M | $24.55M | $25.77M | $27.02M | $27.36M | $29.89M | $29.37M | $32.88M | $31.60M | $23.05M | $12.74M | $12.45M | $5.56M | $4.96M | $4.23M | $6.27M |
| Cost and Expenses | $27.45M | $26.96M | $28.75M | $41.78M | $42.19M | $43.99M | $43.98M | $45.04M | $41.86M | $44.82M | $45.43M | $52.96M | $45.20M | $35.51M | $24.46M | $23.27M | $14.75M | $13.40M | $11.66M | $11.98M |
| Interest Income | $- | $- | $- | $- | $- | $9.16M | $3.39M | $474.00K | $553.00K | $- | $- | $- | $82.00K | $19.00K | $52.00K | $85.00K | $- | $- | $- | $567.00K |
| Interest Expense | $- | $9.07M | $- | $8.51M | $8.68M | $9.26M | $4.50M | $- | $130.18M | $- | $- | $247.00K | $246.00K | $222.00K | $200.00K | $996.00K | $334.00K | $384.00K | $713.00K | $- |
| Depreciation and Amortization | $-65.00K | $7.44M | $7.53M | $7.37M | $7.25M | $7.17M | $7.58M | $7.28M | $4.58M | $4.33M | $4.26M | $4.18M | $3.18M | $2.21M | $2.10M | $4.63M | $-1.32M | $811.00K | $998.00K | $877.00K |
| EBITDA | $-18.82M | $-6.15M | $-10.99M | $-23.46M | $-23.92M | $-22.97M | $-24.48M | $-22.44M | $-26.83M | $-27.89M | $-26.43M | $-31.05M | $-31.83M | $-18.83M | $-9.18M | $-4.14M | $-1.80M | $-605.00K | $30.00K | $-2.39M |
| EBITDA Ratio | -218.09% | -80.61% | -107.50% | -214.34% | -218.51% | -178.52% | -205.25% | -146.42% | -256.81% | -219.52% | -179.27% | -175.12% | -238.12% | -130.14% | -69.67% | -34.40% | -14.06% | -5.10% | 0.28% | -27.35% |
| Operating Income | $-18.82M | $-19.33M | $-18.52M | $-30.83M | $-31.24M | $-31.12M | $-32.23M | $-29.72M | $35.07M | $-32.12M | $-30.69M | $-35.28M | $-31.83M | $-21.08M | $-11.28M | $-11.24M | $-1.91M | $-1.51M | $-1.06M | $-3.26M |
| Operating Income Ratio | -218.09% | -253.40% | -181.16% | -281.70% | -285.34% | -241.90% | -270.22% | -193.94% | 335.63% | -252.85% | -208.16% | -199.00% | -238.12% | -145.64% | -85.60% | -93.47% | -14.90% | -12.76% | -9.98% | -37.39% |
| Total Other Income Expenses Net | $-3.02M | $-3.33M | $-8.74M | $-8.40M | $-8.45M | $-8.18M | $-4.50M | $1.62M | $-206.00K | $1.44M | $4.01M | $21.02M | $28.24M | $60.32M | $-83.45M | $4.29M | $-226.00K | $-285.00K | $-623.00K | $-551.00K |
| Income Before Tax | $-21.84M | $-22.66M | $-27.26M | $-39.43M | $-39.69M | $-39.30M | $-36.73M | $-28.09M | $-95.11M | $-30.68M | $-26.68M | $-14.26M | $-3.60M | $39.25M | $-94.73M | $-6.95M | $-2.14M | $-1.80M | $-1.68M | $-3.81M |
| Income Before Tax Ratio | -253.04% | -297.05% | -266.64% | -360.27% | -362.54% | -305.50% | -307.97% | -183.33% | -910.34% | -241.56% | -180.95% | -80.42% | -26.91% | 271.22% | -718.72% | -57.81% | -16.67% | -15.16% | -15.86% | -43.70% |
| Income Tax Expense | $2.00K | $2.00K | $2.00K | $2.00K | $468.00K | $-61.00K | $-90.00K | $-43.00K | $-236.00K | $-240.00K | $-291.00K | $-1.81M | $-11.42M | $-60.48M | $83.30M | $-5.27M | $1.32M | $-9.00K | $713.00K | $52.00K |
| Net Income | $-21.84M | $-22.66M | $-27.26M | $-39.43M | $-40.16M | $-39.24M | $-36.64M | $-28.05M | $-94.88M | $-30.45M | $-26.39M | $-12.45M | $7.83M | $39.25M | $-94.73M | $-6.95M | $-2.14M | $-1.80M | $-1.68M | $-3.76M |
| Net Income Ratio | -253.06% | -297.08% | -266.66% | -360.29% | -366.82% | -305.02% | -307.22% | -183.05% | -908.08% | -239.67% | -178.97% | -70.21% | 58.53% | 271.22% | -718.72% | -57.81% | -16.67% | -15.16% | -15.86% | -43.11% |
| EPS | $-0.18 | $-0.19 | $-0.26 | $-0.39 | $-0.39 | $-0.38 | $-0.36 | $-0.28 | $-0.94 | $-0.30 | $-0.26 | $-0.12 | $0.08 | $0.44 | $-1.12 | $-0.26 | $-0.03 | $-0.02 | $-0.02 | $-0.04 |
| EPS Diluted | $-7.20 | $-0.19 | $-0.26 | $-0.39 | $-0.39 | $-0.38 | $-0.36 | $-0.28 | $-0.94 | $-0.30 | $-0.26 | $-0.12 | $0.08 | $0.39 | $-1.12 | $-0.26 | $-0.03 | $-0.02 | $-0.02 | $-0.04 |
| Weighted Average Shares Outstanding | 119.71M | 116.47M | 103.97M | 102.14M | 102.03M | 101.94M | 101.90M | 101.40M | 100.93M | 101.05M | 100.73M | 100.36M | 98.16M | 88.81M | 84.71M | 26.62M | 85.72M | 85.72M | 85.72M | 92.80M |
| Weighted Average Shares Outstanding Diluted | 2.99M | 116.47M | 103.97M | 102.14M | 102.03M | 101.94M | 101.90M | 101.40M | 101.20M | 101.05M | 100.73M | 100.36M | 103.52M | 101.52M | 84.71M | 26.62M | 85.72M | 85.72M | 85.72M | 93.04M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $59.17M | $62.79M | $286.49M | $377.58M | $6.26M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $59.17M | $62.79M | $286.49M | $377.58M | $6.26M |
| Net Receivables | $18.88M | $24.31M | $24.56M | $8.07M | $5.52M |
| Inventory | $25.27M | $32.74M | $24.57M | $13.64M | $7.04M |
| Other Current Assets | $4.71M | $5.22M | $4.74M | $3.09M | $417.00K |
| Total Current Assets | $108.04M | $125.07M | $340.36M | $402.38M | $19.24M |
| Property Plant Equipment Net | $464.31M | $472.98M | $335.42M | $126.18M | $92.41M |
| Goodwill | $- | $- | $62.65M | $- | $- |
| Intangible Assets | $77.79M | $80.94M | $84.66M | $1.80M | $2.05M |
| Goodwill and Intangible Assets | $77.79M | $80.94M | $147.31M | $1.80M | $2.05M |
| Long Term Investments | $- | $33.05M | $-1.01M | $15.72M | $30.76M |
| Tax Assets | $- | $200.00K | $1.01M | $-15.72M | $-30.76M |
| Other Non-Current Assets | $47.99M | $26.00K | $15.51M | $15.84M | $30.88M |
| Total Non-Current Assets | $590.09M | $587.20M | $498.24M | $143.82M | $125.33M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $698.13M | $712.27M | $838.60M | $546.20M | $144.57M |
| Account Payables | $5.29M | $14.98M | $20.79M | $10.61M | $8.12M |
| Short Term Debt | $4.71M | $8.65M | $7.03M | $31.20M | $11.86M |
| Tax Payables | $552.00K | $669.00K | $500.00K | $- | $- |
| Deferred Revenue | $1.00M | $200.00K | $214.00K | $2.46M | $4.58M |
| Other Current Liabilities | $4.17M | $995.00K | $14.94M | $6.22M | $9.72M |
| Total Current Liabilities | $15.72M | $25.29M | $43.48M | $50.49M | $34.28M |
| Long Term Debt | $403.36M | $308.51M | $283.63M | $55.56M | $91.21M |
| Deferred Revenue Non-Current | $- | $- | $9.58M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $200.00K | $1.01M | $- | $- |
| Other Non-Current Liabilities | $1.02M | $659.00K | $11.23M | $84.11M | $2.50M |
| Total Non-Current Liabilities | $404.39M | $309.37M | $294.86M | $56.81M | $93.71M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $420.11M | $334.66M | $338.33M | $107.30M | $128.00M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $10.00K | $10.00K | $10.00K | $8.00K | $3.00K |
| Retained Earnings | $-454.12M | $-298.65M | $-118.89M | $-62.50M | $-49.93M |
| Accumulated Other Comprehensive Income Loss | $- | $0 | $0 | $-0 | $- |
| Other Total Stockholders Equity | $732.13M | $676.25M | $619.14M | $414.82M | $66.50M |
| Total Stockholders Equity | $278.02M | $377.61M | $500.26M | $438.90M | $16.58M |
| Total Equity | $278.02M | $377.61M | $500.26M | $438.90M | $16.58M |
| Total Liabilities and Stockholders Equity | $698.13M | $712.27M | $838.60M | $546.20M | $144.57M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $698.13M | $712.27M | $838.60M | $546.20M | $144.57M |
| Total Investments | $45.78M | $33.05M | $-1.01M | $15.72M | $30.76M |
| Total Debt | $408.07M | $313.82M | $287.32M | $83.76M | $103.07M |
| Net Debt | $348.90M | $251.03M | $834.00K | $-293.82M | $96.81M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $22.19M | $40.25M | $57.34M | $59.17M | $77.39M | $90.77M | $101.99M | $62.79M | $99.13M | $140.39M | $210.04M | $286.49M | $194.23M | $416.36M | $312.91M | $377.58M | $4.93M | $6.71M | $-6.26M | $6.26M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $200.07M | $200.03M | $12.52M | $- |
| Cash and Short Term Investments | $22.19M | $40.25M | $57.34M | $59.17M | $77.39M | $90.77M | $101.99M | $62.79M | $99.13M | $140.39M | $210.04M | $286.49M | $194.23M | $416.36M | $312.91M | $377.58M | $4.93M | $6.71M | $6.26M | $6.26M |
| Net Receivables | $16.25M | $14.44M | $15.94M | $18.88M | $18.24M | $19.30M | $22.96M | $24.31M | $23.18M | $23.53M | $24.51M | $24.56M | $16.95M | $13.09M | $11.51M | $8.07M | $8.73M | $6.94M | $- | $5.52M |
| Inventory | $26.04M | $26.28M | $25.99M | $25.27M | $26.68M | $29.87M | $31.75M | $32.74M | $35.20M | $32.73M | $28.23M | $24.57M | $24.15M | $17.65M | $16.85M | $13.64M | $13.21M | $12.82M | $- | $7.04M |
| Other Current Assets | $5.39M | $5.91M | $5.49M | $4.71M | $4.75M | $5.44M | $21.80M | $5.22M | $5.08M | $5.39M | $4.06M | $4.74M | $3.55M | $4.61M | $4.57M | $3.09M | $3.08M | $1.73M | $- | $417.00K |
| Total Current Assets | $69.87M | $86.87M | $104.77M | $108.04M | $127.07M | $145.38M | $178.49M | $125.07M | $162.59M | $202.04M | $266.84M | $340.36M | $238.87M | $451.71M | $345.83M | $402.38M | $29.95M | $28.19M | $6.26M | $19.24M |
| Property Plant Equipment Net | $449.39M | $453.42M | $459.00M | $464.31M | $468.98M | $473.29M | $474.28M | $472.98M | $455.96M | $428.02M | $383.81M | $335.42M | $241.07M | $176.53M | $148.91M | $126.18M | $118.38M | $112.60M | $- | $92.41M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $62.66M | $62.66M | $62.65M | $66.58M | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $75.76M | $76.42M | $77.17M | $77.79M | $78.66M | $79.33M | $80.11M | $80.94M | $81.49M | $82.50M | $83.58M | $84.66M | $86.66M | $1.82M | $1.76M | $1.80M | $1.85M | $1.90M | $- | $2.05M |
| Goodwill and Intangible Assets | $75.76M | $76.42M | $77.17M | $77.79M | $78.66M | $79.33M | $80.11M | $80.94M | $81.49M | $145.16M | $146.24M | $147.31M | $153.24M | $1.82M | $1.76M | $1.80M | $1.85M | $1.90M | $- | $2.05M |
| Long Term Investments | $- | $- | $45.69M | $45.78M | $45.91M | $-44.00K | $45.52M | $33.05M | $33.11M | $13.86M | $-723.00K | $13.89M | $8.68M | $13.93M | $15.73M | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $32.15M | $-45.91M | $44.00K | $107.00K | $29.60M | $246.00K | $483.00K | $723.00K | $26.28M | $4.73M | $-13.93M | $-15.73M | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $48.74M | $49.83M | $2.31M | $2.21M | $46.25M | $46.26M | $119.00K | $-29.38M | $-19.00K | $1.16M | $15.57M | $-24.66M | $3.64M | $1.62M | $73.00K | $15.84M | $29.08M | $29.13M | $-6.26M | $30.88M |
| Total Non-Current Assets | $573.90M | $579.67M | $584.16M | $622.25M | $593.89M | $598.88M | $600.14M | $587.20M | $570.78M | $588.67M | $545.62M | $498.24M | $411.37M | $193.90M | $166.47M | $143.82M | $149.30M | $143.63M | $-6.26M | $125.33M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $643.77M | $666.54M | $688.92M | $730.28M | $720.97M | $744.25M | $778.63M | $712.27M | $733.38M | $790.72M | $812.47M | $838.60M | $650.24M | $645.61M | $512.30M | $546.20M | $179.25M | $171.82M | $- | $144.57M |
| Account Payables | $4.54M | $2.88M | $3.88M | $5.29M | $3.91M | $3.56M | $6.22M | $14.98M | $4.32M | $11.75M | $17.08M | $20.79M | $20.38M | $18.97M | $10.80M | $10.61M | $8.04M | $4.33M | $- | $8.12M |
| Short Term Debt | $9.74M | $14.42M | $4.51M | $8.04M | $7.86M | $8.52M | $13.39M | $8.65M | $8.18M | $8.92M | $6.89M | $7.03M | $6.23M | $6.23M | $6.46M | $31.20M | $3.17M | $3.16M | $- | $11.86M |
| Tax Payables | $1.08M | $1.22M | $912.00K | $552.00K | $1.00M | $1.16M | $871.00K | $669.00K | $852.00K | $1.07M | $824.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $914.00K | $850.00K | $1.15M | $1.00M | $438.00K | $875.00K | $1.31M | $200.00K | $2.00M | $2.29M | $- | $214.00K | $233.00K | $822.00K | $2.34M | $2.46M | $- | $- | $- | $- |
| Other Current Liabilities | $5.05M | $-165.00K | $5.57M | $837.00K | $1.56M | $489.00K | $2.94M | $995.00K | $16.22M | $6.59M | $9.88M | $15.44M | $5.61M | $2.95M | $4.59M | $6.22M | $24.97M | $23.87M | $- | $14.30M |
| Total Current Liabilities | $21.33M | $19.21M | $16.03M | $15.72M | $14.77M | $14.60M | $24.73M | $25.29M | $31.57M | $30.61M | $34.67M | $43.48M | $32.45M | $28.97M | $24.19M | $50.49M | $36.19M | $31.35M | $- | $34.28M |
| Long Term Debt | $403.29M | $408.37M | $405.73M | $403.36M | $400.65M | $398.00M | $395.52M | $308.51M | $308.23M | $284.44M | $284.01M | $283.63M | $51.99M | $50.16M | $55.27M | $55.56M | $99.09M | $99.24M | $- | $91.21M |
| Deferred Revenue Non-Current | $- | $- | $- | $21.93M | $- | $245.00K | $- | $- | $246.00K | $483.00K | $- | $1.01M | $30.91M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $32.15M | $- | $44.00K | $107.00K | $200.00K | $246.00K | $483.00K | $723.00K | $1.01M | $4.73M | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $7.55M | $4.93M | $11.07M | $1.02M | $1.27M | $1.33M | $2.65M | $659.00K | $1.60M | $3.32M | $5.11M | $10.22M | $31.98M | $59.93M | $150.57M | $1.25M | $1.56M | $1.88M | $- | $2.50M |
| Total Non-Current Liabilities | $410.85M | $413.30M | $416.80M | $436.54M | $401.92M | $399.37M | $398.28M | $309.37M | $310.08M | $288.25M | $289.85M | $294.86M | $88.71M | $110.08M | $205.84M | $56.81M | $100.65M | $101.12M | $- | $93.71M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $432.18M | $432.51M | $432.83M | $452.26M | $416.69M | $413.97M | $423.01M | $334.66M | $341.65M | $318.86M | $324.52M | $338.33M | $121.16M | $139.06M | $230.03M | $107.30M | $136.84M | $132.47M | $- | $128.00M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $13.00K | $12.00K | $12.00K | $10.00K | $10.00K | $10.00K | $10.00K | $10.00K | $10.00K | $10.00K | $10.00K | $10.00K | $10.00K | $9.00K | $9.00K | $8.00K | $4.00K | $4.00K | $- | $3.00K |
| Retained Earnings | $-525.88M | $-504.05M | $-481.38M | $-454.12M | $-414.69M | $-374.53M | $-335.29M | $-298.65M | $-270.60M | $-175.72M | $-145.28M | $-118.89M | $-106.44M | $-114.27M | $-153.52M | $-62.50M | $-54.70M | $-52.56M | $- | $-49.93M |
| Accumulated Other Comprehensive Income Loss | $- | $-0 | $- | $- | $0 | $- | $-0 | $0 | $- | $- | $0 | $0 | $-0 | $- | $- | $-0 | $0 | $- | $16.58M | $- |
| Other Total Stockholders Equity | $737.46M | $738.06M | $737.47M | $732.13M | $718.96M | $704.80M | $690.89M | $676.25M | $662.31M | $647.57M | $633.21M | $619.14M | $635.51M | $620.81M | $435.78M | $501.40M | $249.46M | $91.91M | $- | $66.50M |
| Total Stockholders Equity | $211.59M | $234.03M | $256.09M | $278.02M | $304.28M | $330.28M | $355.62M | $377.61M | $391.72M | $471.86M | $487.95M | $500.26M | $529.08M | $506.55M | $282.27M | $438.90M | $42.41M | $39.35M | $16.58M | $16.58M |
| Total Equity | $211.59M | $234.03M | $256.09M | $278.02M | $304.28M | $330.28M | $355.62M | $377.61M | $391.72M | $471.86M | $487.95M | $500.26M | $529.08M | $506.55M | $282.27M | $438.90M | $42.41M | $39.35M | $16.58M | $16.58M |
| Total Liabilities and Stockholders Equity | $643.77M | $666.54M | $688.92M | $730.28M | $720.97M | $744.25M | $778.63M | $712.27M | $733.38M | $790.72M | $812.47M | $838.60M | $650.24M | $645.61M | $512.30M | $546.20M | $179.25M | $171.82M | $16.58M | $144.57M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $643.77M | $666.54M | $688.92M | $730.28M | $720.97M | $744.25M | $778.63M | $712.27M | $733.38M | $790.72M | $812.47M | $838.60M | $650.24M | $645.61M | $512.30M | $546.20M | $179.25M | $171.82M | $16.58M | $144.57M |
| Total Investments | $- | $45.61M | $45.69M | $45.78M | $45.91M | $-44.00K | $45.52M | $33.05M | $33.11M | $13.86M | $-723.00K | $13.89M | $8.68M | $13.93M | $15.73M | $- | $200.07M | $200.03M | $12.52M | $- |
| Total Debt | $413.04M | $419.07M | $410.24M | $408.07M | $405.17M | $403.18M | $405.58M | $313.82M | $313.07M | $290.02M | $287.57M | $287.32M | $55.28M | $53.44M | $58.67M | $83.76M | $111.41M | $111.37M | $- | $100.49M |
| Net Debt | $390.85M | $378.82M | $352.90M | $348.90M | $327.78M | $312.41M | $303.58M | $251.03M | $213.94M | $149.63M | $77.52M | $834.00K | $-138.95M | $-362.92M | $-254.24M | $-293.82M | $106.48M | $104.67M | $6.26M | $94.23M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-155.47M | $-179.76M | $-60.11M | $-12.57M | $-19.51M |
| Depreciation and Amortization | $29.06M | $20.09M | $10.63M | $5.12M | $4.07M |
| Deferred Income Tax | $-199.00K | $-814.00K | $-13.23M | $-5.28M | $4.14M |
| Stock Based Compensation | $56.03M | $56.96M | $55.27M | $3.65M | $5.27M |
| Change in Working Capital | $13.50M | $-19.32M | $-28.87M | $-7.18M | $8.68M |
| Accounts Receivables | $3.77M | $-3.06M | $-10.84M | $-1.60M | $2.19M |
| Inventory | $6.48M | $-11.17M | $-9.80M | $-6.60M | $-2.99M |
| Accounts Payables | $-635.00K | $-1.56M | $2.05M | $993.00K | $3.63M |
| Other Working Capital | $3.89M | $-3.53M | $-10.29M | $30.00K | $5.85M |
| Other Non Cash Items | $9.81M | $61.01M | $-26.65M | $2.46M | $-4.32M |
| Net Cash Provided by Operating Activities | $-47.26M | $-61.84M | $-62.96M | $-13.80M | $-1.67M |
| Investments in Property Plant and Equipment | $-27.68M | $-164.49M | $-185.41M | $-38.27M | $-36.56M |
| Acquisitions Net | $- | $-14.00K | $-151.18M | $9.00K | $875.00K |
| Purchases of Investments | $- | $-18.04M | $- | $- | $-13.41M |
| Sales Maturities of Investments | $- | $18.04M | $- | $- | $12.53M |
| Other Investing Activities | $22.00K | $-17.98M | $422.00K | $9.00K | $-12.53M |
| Net Cash Used for Investing Activities | $-27.66M | $-182.48M | $-336.17M | $-38.26M | $-49.09M |
| Debt Repayment | $83.67M | $23.20M | $213.08M | $2.61M | $33.03M |
| Common Stock Issued | $225.00K | $- | $- | $32.52M | $8.75M |
| Common Stock Repurchased | $- | $-236.00K | $-1.73M | $- | $-4.60M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $131.00K | $-1.21M | $94.01M | $387.55M | $16.32M |
| Net Cash Used Provided by Financing Activities | $84.03M | $21.75M | $306.20M | $422.68M | $53.50M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $9.10M | $-222.57M | $-92.93M | $370.62M | $2.73M |
| Cash at End of Period | $73.50M | $64.40M | $286.97M | $379.90M | $9.28M |
| Cash at Beginning of Period | $64.40M | $286.97M | $379.90M | $9.28M | $6.55M |
| Operating Cash Flow | $-47.26M | $-61.84M | $-62.96M | $-13.80M | $-1.67M |
| Capital Expenditure | $-27.68M | $-164.49M | $-185.41M | $-38.27M | $-36.56M |
| Free Cash Flow | $-74.95M | $-226.32M | $-248.37M | $-52.06M | $-38.23M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-21.84M | $-22.66M | $-27.26M | $-39.43M | $-40.16M | $-39.24M | $-36.64M | $-28.05M | $-94.88M | $-30.45M | $-26.39M | $-12.45M | $7.83M | $39.25M | $-94.73M | $-6.95M | $-2.14M | $-1.80M | $-1.68M | $-3.76M |
| Depreciation and Amortization | $7.33M | $7.44M | $7.53M | $7.37M | $7.21M | $7.13M | $7.38M | $14.77M | $-3.10M | $4.23M | $4.18M | $3.15M | $-3.04M | $2.17M | $2.14M | $4.63M | $-1.32M | $811.00K | $998.00K | $1.02M |
| Deferred Income Tax | $- | $- | $- | $-27.79M | $-44.00K | $-63.00K | $-92.00K | $-47.00K | $-236.00K | $-240.00K | $-291.00K | $-1.81M | $-11.42M | $-60.52M | $80.70M | $-5.28M | $- | $- | $- | $- |
| Stock Based Compensation | $524.00K | $595.00K | $574.00K | $13.81M | $14.25M | $13.91M | $14.06M | $14.56M | $14.41M | $14.23M | $13.75M | $20.18M | $14.40M | $14.03M | $6.67M | $3.12M | $221.00K | $155.00K | $147.00K | $157.00K |
| Change in Working Capital | $-372.00K | $-2.31M | $2.68M | $-986.00K | $5.83M | $137.00K | $7.06M | $2.14M | $-8.20M | $-7.15M | $-6.11M | $-4.67M | $-10.50M | $-2.71M | $-11.00M | $3.25M | $18.00K | $-5.04M | $-5.40M | $1.66M |
| Accounts Receivables | $-3.14M | $1.27M | $2.48M | $-2.57M | $576.00K | $3.09M | $1.90M | $-1.31M | $419.00K | $106.00K | $-2.27M | $-4.50M | $-2.87M | $45.00K | $-3.51M | $1.03M | $-1.48M | $584.00K | $-1.74M | $2.35M |
| Inventory | $887.00K | $- | $-374.00K | $1.01M | $3.09M | $1.63M | $753.00K | $3.10M | $-3.43M | $-6.12M | $-4.71M | $-328.00K | $-5.46M | $-807.00K | $-3.20M | $-436.00K | $-388.00K | $-2.65M | $-3.13M | $-1.08M |
| Accounts Payables | $1.44M | $-896.00K | $-1.18M | $1.43M | $316.00K | $-1.12M | $-1.26M | $3.08M | $-1.95M | $-3.42M | $725.00K | $1.16M | $-1.08M | $2.64M | $-669.00K | $-1.40M | $2.98M | $-860.00K | $268.00K | $248.25K |
| Other Working Capital | $443.00K | $-2.68M | $1.76M | $-846.00K | $1.84M | $-3.46M | $5.66M | $-2.73M | $-3.24M | $2.28M | $155.00K | $-997.00K | $-1.09M | $-4.59M | $-3.62M | $4.05M | $-1.10M | $-2.12M | $-801.00K | $387.00K |
| Other Non Cash Items | $-147.00K | $-2.03M | $18.19M | $64.39M | $2.73M | $2.84M | $2.36M | $-7.62M | $71.81M | $-415.00K | $-2.75M | $-19.92M | $-22.07M | $-653.00K | $2.02M | $-2.16M | $3.19M | $1.10M | $323.00K | $2.02M |
| Net Cash Provided by Operating Activities | $-14.50M | $-18.97M | $-12.99M | $17.36M | $-10.18M | $-15.29M | $-5.87M | $-4.25M | $-20.19M | $-19.79M | $-17.61M | $-15.52M | $-24.80M | $-8.43M | $-14.21M | $-3.38M | $-26.00K | $-4.77M | $-5.62M | $1.09M |
| Investments in Property Plant and Equipment | $-3.72M | $-1.80M | $-1.97M | $-1.96M | $-2.68M | $-6.64M | $-16.40M | $-30.85M | $-24.78M | $-49.95M | $-58.90M | $-88.61M | $-44.89M | $-28.01M | $-23.89M | $-13.09M | $-6.10M | $-3.74M | $-15.34M | $-13.66M |
| Acquisitions Net | $- | $- | $- | $4.00K | $18.00K | $- | $- | $- | $- | $55.00K | $-14.00K | $-151.18M | $-151.18M | $340.00K | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $-18.04M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $1.17M | $- | $- | $4.00K | $18.00K | $- | $- | $- | $-18.04M | $55.00K | $- | $151.26M | $-151.18M | $340.00K | $- | $- | $- | $9.00K | $- | $-7.15M |
| Net Cash Used for Investing Activities | $-2.55M | $-1.80M | $-1.97M | $-1.96M | $-2.66M | $-6.64M | $-16.40M | $-30.85M | $-42.82M | $-49.89M | $-58.92M | $-88.53M | $-196.07M | $-27.67M | $-23.89M | $-13.09M | $-6.10M | $-3.73M | $-15.34M | $-20.80M |
| Debt Repayment | $-977.00K | $3.61M | $-606.00K | $-593.00K | $-693.00K | $-6.25M | $124.51M | $-618.00K | $23.90M | $-44.00K | $-44.00K | $240.00M | $-11.00K | $11.00K | $-26.92M | $-612.00K | $14.00K | $1.17M | $2.03M | $19.48M |
| Common Stock Issued | $-141.00K | $8.00K | $4.65M | $225.00K | $153.00K | $- | $129.00K | $- | $- | $120.00K | $373.00K | $- | $- | $- | $- | $3.52M | $4.00M | $91.00K | $24.92M | $8.13M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $-61.00K | $- | $- | $- | $- | $2.00K | $-2.00K | $-75.00K | $-815.00K | $- | $- | $- | $- | $100.00K |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $48.00K | $-7.00K | $8.99M | $-90.00K | $-1.00K | $-260.00K | $-32.91M | $-347.00K | $-941.00K | $37.00K | $122.00K | $-45.28M | $300.00K | $137.74M | $351.00K | $387.31M | $254.00K | $-82.00K | $64.00K | $-740.00K |
| Net Cash Used Provided by Financing Activities | $-1.07M | $3.61M | $13.04M | $-33.75M | $-541.00K | $-6.51M | $91.54M | $-1.28M | $22.96M | $-7.00K | $78.00K | $194.72M | $289.00K | $137.75M | $-26.57M | $390.22M | $4.26M | $1.18M | $27.01M | $18.84M |
| Effect of Forex Changes on Cash | $- | $- | $- | $-806.00K | $20.64M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.02M | $- | $- |
| Net Change in Cash | $-18.12M | $-17.16M | $-1.83M | $-18.22M | $-13.38M | $-28.44M | $69.27M | $-36.39M | $-40.05M | $-69.69M | $-76.44M | $90.67M | $-220.58M | $101.65M | $-64.67M | $373.75M | $-1.86M | $-4.30M | $6.06M | $-870.00K |
| Cash at End of Period | $36.30M | $54.42M | $57.34M | $59.17M | $91.85M | $105.24M | $133.68M | $64.40M | $100.79M | $140.84M | $210.53M | $286.97M | $196.30M | $416.88M | $315.23M | $379.90M | $6.15M | $8.01M | $12.32M | $9.28M |
| Cash at Beginning of Period | $54.42M | $71.58M | $59.17M | $77.39M | $105.24M | $133.68M | $64.40M | $100.79M | $140.84M | $210.53M | $286.97M | $196.30M | $416.88M | $315.23M | $379.90M | $6.15M | $8.01M | $12.32M | $6.26M | $10.15M |
| Operating Cash Flow | $-14.50M | $-18.97M | $-12.99M | $17.36M | $-10.18M | $-15.29M | $-5.87M | $-4.25M | $-20.19M | $-19.79M | $-17.61M | $-15.52M | $-24.80M | $-8.43M | $-14.21M | $-3.38M | $-26.00K | $-4.77M | $-5.62M | $1.09M |
| Capital Expenditure | $-3.72M | $-1.80M | $-1.97M | $-1.96M | $-2.68M | $-6.64M | $-16.40M | $-30.85M | $-24.78M | $-49.95M | $-58.90M | $-88.61M | $-44.89M | $-28.01M | $-23.89M | $-13.09M | $-6.10M | $-3.74M | $-15.34M | $-13.66M |
| Free Cash Flow | $-18.21M | $-20.77M | $-14.96M | $15.40M | $-12.86M | $-21.93M | $-22.27M | $-35.11M | $-44.97M | $-69.74M | $-76.51M | $-104.14M | $-69.69M | $-36.45M | $-38.10M | $-16.47M | $-6.12M | $-8.51M | $-20.95M | $-12.56M |
Danimer Scientific, Inc., a performance polymer company, develops, produces, and provides bioplastic replacements for traditional petroleum-based plastics. It produces polyhydroxyalkanoate, a biodegradable plastic feedstock alternative used in a range of plastic applications, including films, straws, food containers, and other things under the Nodax brand name; polylactic acid-based resins for coating disposable paper cups; and other biopolymers. The company offers its products for biopolymers, including additives, aqueous coatings, fibers, filaments, films, thermoforming, and injection-molded articles. It also markets its products to consumer packaging brand owners, converters, and manufacturers in the plastics industry. Danimer Scientific, Inc. was founded in 2004 and is headquartered in Bainbridge, Georgia.
$0.35
Stock Price
$1.06M
Market Cap
900
Employees
Bainbridge, GA
Location
Revenue (FY 2023)
$46.68M
-12.3% YoY
Net Income (FY 2023)
$-155.47M
13.5% YoY
EPS (FY 2023)
$-1.52
14.6% YoY
Free Cash Flow (FY 2023)
$-74.95M
66.9% YoY
Profitability
Gross Margin
-57.7%
Net Margin
-333.0%
ROE
-55.9%
ROA
-22.3%
Valuation
P/E Ratio
-26.77
P/S Ratio
89.15
EV/EBITDA
-46.92
Market Cap
$1.06M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-47.26M
23.6% YoY
Free Cash Flow
$-74.95M
66.9% YoY
Balance Sheet Summary
Total Assets
$698.13M
-2.0% YoY
Total Debt
$408.07M
30.0% YoY
Shareholder Equity
$278.02M
-27.0% YoY
Dividend Overview
No Dividend Data
Danimer Scientific, Inc. doesn't currently pay dividends.
Danimer Scientific Dividends
Explore Danimer Scientific's dividend history, including dividend yield, payout ratio, and historical payments.
Danimer Scientific News
Read the latest news about Danimer Scientific, including recent articles, headlines, and updates.
Danimer Scientific Announces Common Stock Expected to Begin Trading Promptly on OTCQX Marketplace
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that it received notice the New York Stock Exchange (“NYSE”) suspended trading of its common stock on the NYSE effective immediately and started the process to delist its common stock from the NYSE. The start of the delisting process follows the NYSE's determinatio.
NYSE to Commence Delisting Proceedings Against Danimer Scientific, Inc. (DNMR)
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the Class A common stock of Danimer Scientific, Inc. (the “Company”) — ticker symbol DNMR — from the NYSE. Trading in the Company's Class A common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company's Class A common stock pursuant to Section 802.01B of the NYSE's Listed Compa.
Danimer Scientific Takes Action to Strengthen Capital Structure
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that the Company issued a super senior secured promissory note (the “Secured Loan”) in an aggregate principal amount of $11,250,000 to certain lenders under its existing term loan financing agreement, as well as certain additional lenders. The Secured Loan provides.
TerraNova Capital Equities announces three transactions totaling $45 Million
NEW YORK , Nov. 20, 2024 /PRNewswire/ -- TerraNova Capital Equities, inc. (TerraNova), a leading financial advisory firm, is pleased to announce that its Structure Finance Group acted as sole advisor on three recent transactions: TerraNova Structured Finance Group acted as the sole advisor to Danimer Scientific, Inc. (NYSE: DNMR) on a $20 Million revolving credit facility.
Danimer Scientific, Inc. (DNMR) Q3 2024 Earnings Call Transcript
Danimer Scientific, Inc. (NYSE:DNMR ) Q3 2024 Earnings Conference Call November 19, 2024 10:00 AM ET Company Participants Rich Altice - Interim CEO Mike Hajost - CFO Conference Call Participants Unidentified Company Representative Thank you, operator. Good morning, everyone, and thank you for joining us today on Danimer Scientific's 2024 Third Quarter Earnings Call.
Danimer Scientific Announces Third Quarter 2024 Results
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today financial results for its third quarter ended September 30, 2024. Richard N. Altice, Interim Chief Executive Officer of Danimer, commented, “We completed the third quarter in line with our expectations considering the temporary impact of Starbucks' reapportionment.
Danimer Scientific Announces Release Date for Third Quarter 2024 Results
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading, next-generation bioplastics company focused on the development and production of biodegradable materials, announced today that the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 19, 2024. A webcast and conference call will be held that same day at 10:00 a.m. Eastern Time to review the Company's third quarter results. The web.
Danimer Scientific Announces Intention to Complete a Reverse Stock Split
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or “Company”), a leading, next-generation biotechnology company focused on the production of biomaterials, announced today that, following approval by the Company's stockholders and its Board of Directors, the Company will effect a reverse stock split (“Reverse Stock Split”) of Danimer's Class A common stock, par value $0.0001 per share (“Common Stock”), at a ratio of 1-for-40 (the “Reverse Stock Split Ratio”), w.
Danimer Scientific Announces Second Circuit Court Affirms Dismissal of Class Action Lawsuit
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Company” or “Danimer Scientific”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced that, on September 27, 2024, the United States Court of Appeals for the Second Circuit affirmed the 2023 Order of the United States District Court for the Eastern District of New York dismissing a previously disclosed putative class action complaint captioned In r.
Ningbo Homelink Eco-iTech and Danimer Scientific Announce Commercial Launch of Home Compostable Extrusion Coating Biopolymer Based on PHA
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer”), a leading, next-generation biotechnology company focused on the production of biodegradable materials, and Ningbo Homelink Eco-iTech Co. Ltd. (“Homelink”), a leading manufacturer of disposable tableware, have announced commercial launch of home compostable extrusion coating biopolymers made with Danimer's signature polyhydroxyalkanoate (PHA), Nodax®. Homelink's cups, coated with Nodax® PHA-based biopolymer, wil.
DoD Makes Award to Danimer Scientific via the Distributed Bioindustrial Manufacturing Program
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer”), a leading, next-generation biotechnology company focused on the production of biomaterials, announces an award from the U.S. Department of Defense via the Distributed Bioindustrial Manufacturing Program (DBIMP). Danimer Scientific has been awarded $1.36 million to develop plans for a facility to produce biobased polyols that can be converted into high-performance coatings for ships, marine vessels, and steel pi.
Danimer Scientific, Inc (DNMR) Q2 2024 Earnings Call Transcript
Danimer Scientific, Inc (NYSE:DNMR ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Blake Chamblee - Director of Financial Reporting Stephen Croskrey - Chairman and Chief Executive Officer Mike Hajost - Chief Financial Officer Conference Call Participants Jon Tanwanteng - CJS Securities Operator Greetings. Welcome to the Danimer Scientific 2024 Second Quarter Earnings Call.
Danimer Scientific Announces Release Date for Second Quarter 2024 Results
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading, next-generation bioplastics company focused on the development and production of biodegradable materials, announced today that the Company will release its second quarter 2024 financial results after the market closes on Thursday, August 8, 2024. A webcast and conference call will be held that same day at 4:30 p.m. Eastern Time to review the Company's second quarter results, discuss.
Danimer Scientific Completes Dividend Distribution of Warrants to Stockholders
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Company” or “Danimer Scientific”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced the completion of a previously announced pro-rata dividend distribution of warrants (“Dividend Warrants”) to holders of the Company's Class A Common Stock, par value $0.0001 per share (“Common Stock”), as of May 13, 2024 (“Record Date”). The stockholders of.
Danimer Scientific Receives Continued Listing Standard Notice from NYSE
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading, next-generation bioplastics company focused on the production of biodegradable materials, announced that it received a notice from the New York Stock Exchange (“NYSE”) on May 21, 2024, that the Company is not currently in compliance with the NYSE's continued listing standard requiring listed-company stock to maintain an average closing price of not less than $1.00 per share over a pe.
Danimer Scientific Announces Steve Croskrey Retirement and Related Changes to the Company's Board of Directors
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today that Stephen E. Croskrey has informed the Board of Directors that he will retire as Chief Executive Officer not later than the end of this calendar year. Mr. Croskrey's employment contract expires at the end of 2024 following nine years leading Danimer's mission to.
Danimer Scientific, Inc. (DNMR) Q1 2024 Earnings Call Transcript
Danimer Scientific, Inc. (NYSE:DNMR ) Q1 2024 Results Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Blake Chamblee - Director of Financial Reporting Stephen Croskrey - Chairman and Chief Executive Officer Mike Hajost - Chief Financial Officer Conference Call Participants Jon Tanwanteng - CJS Securities Dan Rizzo - Jefferies LLC Operator Greetings. Welcome to the Danimer Scientific 2024 First Quarter Earnings Call.
Danimer Scientific Reveals New Branding and New Applications Based on PHA During NPE 2024
BAINBRIDGE, Ga.--(BUSINESS WIRE)---- $DNMR--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next-generation bioplastics company focused on the development and production of PHA biopolymers, is unveiling new commercial applications and branding during NPE 2024, North America's largest plastics tradeshow, taking place this week in Orlando, FL. A more perfect polymer™ takes center stage at NPE 2024. Danimer's signature PHA, Nodax®, represents a more perfect polymer revolution.
Danimer Scientific Announces Proposed Pro-Rata Distribution of Warrants to Purchase Common Stock
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Company” or “Danimer Scientific”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced a proposed pro-rata dividend distribution of warrants (“Dividend Warrants”) to holders of the Company's Class A Common Stock, par value $0.0001 per share (“Common Stock”) as of May 13, 2024 (“Record Date”). Subject to the Company's stockholders approving a p.
Danimer Scientific Announces Release Date for First Quarter 2024 Results
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading, next-generation bioplastics company focused on the development and production of biodegradable materials, announced today that the Company will release its first quarter 2024 financial results after the market closes on Tuesday May 7, 2024. A webcast and conference call will be held that same day at 4:30 p.m. Eastern Time to review the Company's first quarter results, discuss recent.
Danimer Scientific Announces $20 Million Asset-Based Revolving Credit Facility
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (the “Company” or “Danimer Scientific”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today, that on April 19, 2024, it entered into an asset-based revolving credit and security agreement with Mountain Ridge Capital secured primarily by the Company's accounts receivable and inventory. The credit and security agreement provides for borrowings un.
Down -41.74% in 4 Weeks, Here's Why Danimer Scientific (DNMR) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Danimer Scientific (DNMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Danimer Scientific Announces Fourth Quarter and Full Year 2023 Results
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today financial results for its fourth quarter and full year, ended December 31, 2023. Stephen E. Croskrey, Chairman and Chief Executive Officer of Danimer, commented, “While 2023 was a challenging year for the Company, we are greatly encouraged by the successes we had a.
Danimer Scientific Announces Closing of $15 Million Registered Direct Offering
BAINBRIDGE, Ga.--(BUSINESS WIRE)--Danimer Scientific, Inc. (NYSE: DNMR) (the “Company” or “Danimer Scientific”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced the closing of its previously announced registered direct offering for the purchase and sale of 15,000,000 shares of common stock (or common stock equivalent in lieu thereof) at a purchase price of $1.00 per share (or per common stock equivalent in lieu.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DNMR.